Sellas reports Q2 2026 results, nears key REGAL trial milestone
Sellas said it is approaching the 80th event needed for final analysis of the Phase 3 REGAL trial in AML, while its SLS009 frontline trial keeps enrolling.
SEC filing
Latest
2 stories
Tuesday, August 11
Monday, July 27
SELLAS loses arbitration against 3D Medicines over GPS milestone dispute
An HKIAC arbitrator sided with 3D Medicines and ordered SELLAS to pay about $1.0 million toward its legal costs, while $191.5 million in milestone payments remain under the license deal.
SEC filing